Combined antibacterial effect on Gram-positive bacteria

The term Combined antibacterial effect on Gram-positive bacteria does not refer to a single molecular target or receptor but rather describes a pharmacological phenomenon where multiple antimicrobial agents are used in concert to inhibit or kill Gram-positive pathogens (StatPearls, 2023). Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae, possess a thick peptidoglycan cell wall that is a primary target for many antibiotics (NIH, 2022). Combining drugs can result in synergy, where the total effect is greater than the sum of individual effects, often achieved by targeting distinct biochemical pathways like cell wall assembly and ribosomal protein synthesis (PubMed, 2021). This strategy is clinically vital for treating multidrug-resistant infections and reducing the likelihood of resistance development during therapy (CDC, 2020). However, as a target name, this entry is considered incorrect as it represents a therapeutic outcome or study endpoint rather than a specific biological molecule. In clinical practice, the efficacy of these combinations is often measured using the Fractional Inhibitory Concentration Index to determine if the interaction is synergistic, additive, or antagonistic (Journal of Antimicrobial Chemotherapy, 2019). Common examples include the use of beta-lactams with aminoglycosides to treat Enterococcal endocarditis, where the cell-wall active agent facilitates the entry of the protein-synthesis inhibitor (Mayo Clinic, 2022).

Other names

Synergistic antibacterial activityAntibiotic synergyCombination antibiotic therapy against Gram-positive bacteriaPolypharmacy antimicrobial effect

Synergistic or additive inhibition of bacterial physiological processes, such as simultaneous disruption of cell wall synthesis and protein synthesis, or enhancement of drug uptake through increased membrane permeability.